Patients who have heart failure with preserved ejection fraction (HFpEF) and high blood pressure in the lungs (pulmonary ...
The algorithm integrates with EHR systems and ECG platforms, operating within the health system without external data ...
Investor's Business Daily on MSN
United Therapeutics soars as study results bring 'new era'
United Therapeutics shares soared Monday on a "new era" for Tyvaso.
Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for Merck’s WINREVAIR in Adults With CpcPH-HFpEF ...
PH is a progressive, life-threatening pulmonary vascular disease estimated to affect up to 1% of the global population. 1 It is often difficult to diagnose 2 due to non-specific early symptoms, such ...
A diagnostic panel incorporating let-7a-5p, miR-9-5p, and miR-31-5p achieved an area under the curve of 0.862 in differentiating patients with pulmonary arterial hypertension from healthy people.
Pulmonary arterial hypertension, or PAH, is a rare and severe disease characterized by elevated blood pressure in the ...
Merck (NYSE:MRK) is approaching phase 2 data for Winrevair in pulmonary hypertension. Results will focus on the 6 minute walk ...
Pulmonary hypertension in kidney transplant recipients is associated with lower graft and patient survival. Pre-existing pulmonary hypertension in kidney transplant recipients (PHTN) is associated ...
Gossamer Bio Inc. (NASDAQ:GOSS) is one of the penny stocks with the potential to rise 1000 percent. Gossamer Bio remained in focus in March 2026 after its late-February Phase 3 PROSERA study of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results